Clinical trial
Memantine for Agitation and Aggression in Severe Alzheimer's Disease
NCT00401167 · Sunnybrook Health Sciences Centre, Other · Completed
Key facts
| NCT number | NCT00401167 |
|---|---|
| Title | Memantine for Agitation and Aggression in Severe Alzheimer's Disease |
| Official title | Phase IV-An Open-Label Prospective Study of Memantine in Institutionalized Patients With Severe Alzheimer's Disease and Significant Behavioural and Psychological Symptoms of Dementia |
| Lead sponsor | Sunnybrook Health Sciences Centre, Other |
| Collaborators | Lundbeck Canada Inc. Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease |
| Intervention type | Drug |
| Interventions | memantine |
| Enrollment | 31 |
| Start date | Nov 1, 2006 |
| Primary completion | Jan 1, 2010 |
| Completion | Jan 1, 2010 |
| First posted | Nov 17, 2006 |
| Last update posted | Jan 31, 2024 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: